ASPEN PHARMACARE HOLDINGS LIMITED - 2014 Anti-Retroviral Tender Results

2014 Anti-Retroviral Tender Results

ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa)
Registration number 1985/0002935/06
Share code: APN
ISIN: ZAE000066692
("Aspen Holdings" or "the Company")


2014 ANTI-RETROVIRAL TENDER RESULTS

Following the announcement of the Anti-Retroviral (ARV) Tender results by the South
African National Treasury Department, Aspen Pharmacare Holdings Limited is pleased to
announce that its South African operating company (Pharmacare Limited t/a Aspen
Pharmacare) has been successful in winning a number of key products in the tender Aspen’s
award included 25% of the Fixed Dose Combination (FDC) containing Tenofovir,
Emtracitibine and Efavirenz, which will be used to treat upwards of 80% of 1st line adult
treatment , in spite of strong competition. The tender is effective for a period of three years,
commencing 1 April 2015.

Aspen secured R2,7 billion or approximately 20% of the awarded tender value based upon
expected future demand as published in the invitation to tender. The tender value is
estimated to be approximately R14 billion over 3 years. The South African ARV Tender is
the largest of its kind in the world. Aspen has been a leading supplier to this tender since
inception of the programme, providing a consistent and reliable supply of high-quality ARV
products to the State.

Aspen was awarded a share of the following products:

Product                                            % Awarded to Aspen
Abacavir Solution 20mg/ml                          45%
Atazanavir 150mg                                   36%
Duranavir 600mg                                    100%
Etravarine 100mg                                   100%
Lamivudine 150mg (of tendered quantity)            100%
Nevirapine                                         40%
Stavudine 15mg                                     100%
Stavudine 20mg                                     100%
Stavudine 30mg                                     100%
Tenofovir (of tendered quantity)                   25%
Tenofovir, Emtracitibine, Efavirenz                25%

These tender results again confirm Aspen`s reputation for cost competitiveness against both
local and foreign suppliers. Aspen`s range of ARV`s are produced at its world-class
manufacturing facilities in Port Elizabeth, South Africa. This has resulted in unlocking
capacity to accommodate growing demand from Aspen`s domestic and foreign territories
and also contributed towards further optimizing manufacturing efficiencies.


Durban
24 December 2014

Sponsor
Investec Bank Limited

Date: 24/12/2014 11:45:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.